Drug Trial Radar · NCT04463251
Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction
Last checked: Nov 20, 2026Latest source record: Jun 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
102
Actual
Start
Dec 7, 2020
Primary completion
Nov 3, 2021
Study completion Oct 10, 2022
Sponsor
- Lead sponsor
- R-Pharm Overseas, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Cromos Pharma LLC; Data Management 365; Keystat, LLC; R-Pharm; K-Research, LLC
- First posted
- Jul 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of the study was to evaluate the effect of single administration of RPH-104 at 80 mg and 160 mg on parameters of systemic inflammation and outcomes of the disease in subjects with ST-segment elevation myocardial infarction (STEMI)
Conditions
- Acute ST Segment Elevation Myocardial Infarction
Interventions
RPH-104 80 mgBiological
solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL transparent glass vial
PlaceboDrug
Normal Saline (0.9% Sodium Chloride solution for Injection), 2 mL in the 4-mL transparent glass vial
Primary outcomes
What the sponsor says the trial is designed to measure.
- High-sensitive С-reactive Protein (hsCRP) Area Under Curve (AUC) From Baseline Until Day 14 (Multiple Imputation Procedure)Time frame: Day 1 until Day 14
- High-sensitive С-reactive Protein (hsCRP) Area Under Curve (AUC) From Baseline Until Day 14 (сomplete Cases)Time frame: Day 1 until Day 14
- High-sensitive С-reactive Protein (hsCRP) Area Under Curve (AUC) From Baseline Until Day 14 (Sensitivity Analysis, Multiple Imputation Procedure)Time frame: Day 1 until Day 14
- High-sensitive С-reactive Protein (hsCRP) Area Under Curve (AUC) From Baseline Until Day 14 (Sensitivity Analysis, Complete Cases)Time frame: Day 1 until Day 14
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
Cleveland Clinic
Cleveland, Ohio
University of Virginia Health System
Charlottesville, Virginia
VCU Health-Virginia Commonwealth University Health
Richmond, Virginia
State Budgetary Healthcare Institution of Moscow "City Clinical Hospital named after V.V. Vinogradov of Moscow Healthcare Department"
Moscow, Russia
State Institution of Healthcare in Moscow "City Clinical Hospital № 51 Moscow Health Department"
Moscow, Russia
Federal State Budgetary Institution "National Medical Research Center for Cardiology" of the Ministry of Healthcare of the Russian Federation
Moscow, Russia
State Budgetary Healthcare Institution of Moscow "City Clinical Hospital named after V.V. Veresaev of Moscow Healthcare Department"
Moscow, Russia
State Autonomous Healthcare Institution of the Perm Territory "City Clinical Hospital No. 4"
Perm, Russia
Ryazan State Medical University n.a. academician I.P. Pavlov on the basis of Regional Clinical cardiology Dispensary
Ryazan, Russia
St. Petersburg State Budgetary Healthcare Institution "Saint Martyr Elizabeth City Hospital"
Saint Petersburg, Russia
The State Budgetary Health Care Institution of the Yaroslavl Region "Regional Clinical Hospital"
Yaroslavl, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.